Press release
Paris, 12th March 2019
SGH Healthcaring, which specialises in medical devices, has acquired Eskiss Packaging and the Dosapharm laboratory Levine Keszler is advising SGH Healthcaring.
SGH Healthcaring, in an LBO with Mérieux Equity Partners and Gimv, announced on 11 March 2019 the completion of two new acquisitions: Eskiss Packaging and the Dosapharm laboratory.
SGH Healthcaring’s ambitions are clear: to become one of Europe’s leading plastics manufacturers of medical devices and liquid and solid drug delivery systems. With the acquisition of Eskiss Packaging and the Dosapharm laboratory, SGH Healthcaring now not only has a new technology, injection blow moulding, but is also strengthening its presence in the food supplements sector.
With these two new acquisitions, which come just over six months after the takeovers of Rovipharm and RR Plastiques, the SGH Healthcaring group now has 200 employees, three sites in France and is set to exceed €40 million in sales in 2019. Over the next five years, Jérôme Empereur, CEO of SGH Healthcaring, hopes to see this figure rise to €100 million ‘so that we can position ourselves to win major tenders’. At the end of the year, a new plant is due to open in Portugal. This will enable the Group to ‘internalise subcontracting’. It will be based on the same standards as the Saint-Marcellin plant (Isère), which opened in October 2017, and will carry out assembly operations with a view to improving efficiency and reducing costs.
Levine Keszler advised SGH Healthcaring on these operations.
Counsel to SGH Healthcaring:
Levine Keszler (Nicolas de Courtivron, partner; Pierre Plettener)
Legal and financial DD:
D‘Ornano & Associés (Raphaëlle d’Ornano, partner)
Counsel to the sellers
CJA avocats (Marc Chobert, partner; Mathieu Layral)
